Association between CYP2D6 phenotype and recurrence of Plasmodium vivax infection in south Korean patients

• Published in: Malaria Journal
• Main Authors: Sungim Choi, Heun Choi, Seong Yeon Park, Yee Gyung Kwak, Je Eun Song, So Youn Shin, Ji Hyeon Baek, Hyun-IL Shin, Shin-Hyung Cho, Sang-Eun Lee, Jeong-Ran Kwon, Sookkyung Park, Miyoung Kim, Hong Sang Oh, Yong Chan Kim, Min Jae Kim, Joon-Sup Yeom
• Format: Article in Journal/Newspaper
• Language: English
• Published: BMC 2022
• Subjects: CYP2D6; Primaquine; Relapse; Plasmodium vivax; Arctic medicine. Tropical medicine; RC955-962; Infectious and parasitic diseases; RC109-216; Arctic
• Online Access: https://doi.org/10.1186/s12936-022-04311-6; https://doaj.org/article/c81ae53198ca44f9837025cd8aca0d2d

Abstract Background Primaquine is activated by CYP2D6 in the hepatocytes. In Korea, primaquine is the only hypnozoitocidal agent used for patients with vivax malaria. Thus, patients with poor CYP2D6 activity could have an increased risk of primaquine failure and subsequent relapse. The study sought to identify the association between CYP2D6 phenotype and recurrence of malaria in Korean patients. Methods A total of 102 patients with vivax malaria were prospectively enrolled from eight institutions in Korea. An additional 38 blood samples from patients with recurred vivax malaria were provided by the Korea Disease Control and Prevention Agency. Malaria recurrence was defined as more than one episode of vivax malaria in the same or consecutive years. CYP2D6 star alleles, phenotypes, and activity scores were examined. Results Genotyping for CYP2D6 was successful in 101 of the prospectively enrolled patients and 38 samples from the Korea Disease Control and Prevention Agency, of which 91 were included in the no-recurrence group and 48 were included in the recurrence group. Reduced CYP2D6 activity (intermediate metabolizer) phenotype was more common in the recurrence group than in the no-recurrence group (OR, 2.33 (95% CI, 1.14–4.77); p = 0.02). Patients with lower CYP2D6 activity had a higher probability of recurrence (p = 0.029). Conclusion This study suggests that CYP2D6 polymorphism may affect primaquine efficacy and thus Plasmodium vivax recurrence in Korea.